EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access

An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate

Ian M McGowan iD, Ratiya Pamela Kunjara Na Ayudhya, Rhonda M Brand, Mark A Marzinke, Craig W Hendrix, Sherri Johnson, Jeanna Piper, Timothy H Holtz, Marcel E Curlin, Anupong Chitwarakorn, Boonyos Raengsakulrach, Gustavo Doncel und 3 weitere

AIDS Research and Human Retroviruses · 2022-04 · 38 (4) · 279-287

DOI: 10.1089/aid.2021.0115 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift AIDS Research and Human Retroviruses, online erschienen am 06.04.2022. Verfasst von Ian M McGowan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, HIV-1, Pre-Exposure Prophylaxis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Microbicide Trials Network-017 study was undertaken to characterize the safety, acceptability, pharmacokinetic (PK), and pharmacodynamic profile of the reduced-glycerin (RG) 1% tenofovir (RG-TFV) gel compared to oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF). The study was a Phase 2, three-period, randomized sequence, open-label, expanded safety and acceptability crossover study. In each 8-week study period, HIV-1-uninfected participants were randomized to RG-TFV rectal gel daily or RG-TFV rectal gel before and after receptive anal intercourse (RAI) (or at least twice weekly in the event of no RAI), or daily oral FTC/TDF. A mucosal substudy was conducted at sites in the United States and Thailand. Samples were collected to evaluate PK and ex vivo biopsy challenge with HIV-1. A total of 195 men who have sex with men and transgender women were enrolled in the parent study and 37 in the mucosal substudy. As previously reported, both products were found to be safe and acceptable. Systemic TFV concentrations were significantly higher following oral exposure and daily rectal administration compared to RAI-associated product use ( p < .001). All three routes of pre-exposure prophylaxis (PrEP) administration resulted in the inhibition of explant infection ( p < .05), and there was a significant inverse correlation between explant HIV-1 p24 and tissue concentrations of TFV and FTC ( p < .0001). Despite significant differences in systemic and mucosal drug concentrations, all three PrEP regimens were able to protect rectal explants from ex vivo HIV infection. These data suggest that there is a rationale for co-development of oral and topical antiretroviral PrEP for HIV prevention. Clinical Trial Registration number: NCT01687218.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsHIV-1Pre-Exposure ProphylaxisSexual and Gender MinoritiesCross-Over StudiesEmtricitabineFemaleHomosexuality, MaleHumansMaleReverse Transcriptase InhibitorsTenofovir

Stichwörter der Autor:innen

HIVemtricitabinemicrobicidepreventionrectaltenofovir

Substanzen

Anti-HIV AgentsReverse Transcriptase InhibitorsTenofovirEmtricitabine

Autor:innen und Institutionen

  • Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Orion Biotechnology, Ottawa, Ontario, Canada.
  • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department of Medicine, The Johns Hopkins University, Baltimore, Maryland, USA.
  • FHI 360, Durham, North Carolina, USA.
  • National Institute of Allergy and Infectious Disease, Bethesda, Maryland, USA.

ORCID-Profile: Ian M McGowan, Ross D Cranston

Förderung

  • NIAID NIH HHS

Zitieren

APA

McGowan, I. M., Kunjara Na Ayudhya, R. P., Brand, R. M., Marzinke, M. A., Hendrix, C. W., Johnson, S., Piper, J., Holtz, T. H., Curlin, M. E., Chitwarakorn, A., Raengsakulrach, B., Doncel, G., Schwartz, J. L., Rooney, J. F., & Cranston, R. D. (2022). An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate. AIDS Research and Human Retroviruses, 38(4), 279-287. https://doi.org/10.1089/aid.2021.0115

Vancouver

McGowan IM, Kunjara Na Ayudhya RP, Brand RM, Marzinke MA, Hendrix CW, Johnson S, et al. An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate. AIDS Research and Human Retroviruses. 2022;38(4):279-287. doi:10.1089/aid.2021.0115

BibTeX
@article{McGowan2022,
  author = {McGowan, Ian M and Kunjara Na Ayudhya, Ratiya Pamela and Brand, Rhonda M and Marzinke, Mark A and Hendrix, Craig W and Johnson, Sherri and Piper, Jeanna and Holtz, Timothy H and Curlin, Marcel E and Chitwarakorn, Anupong and Raengsakulrach, Boonyos and Doncel, Gustavo and Schwartz, Jill L and Rooney, James F and Cranston, Ross D},
  title = {An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate},
  journal = {AIDS Research and Human Retroviruses},
  year = {2022},
  volume = {38},
  number = {4},
  pages = {279--287},
  doi = {10.1089/aid.2021.0115}
}
Kostenlos starten →